{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:27:53Z","timestamp":1780446473644,"version":"3.54.1"},"reference-count":19,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2020.34776","type":"journal-article","created":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T16:30:45Z","timestamp":1611765045000},"page":"e2034776","source":"Crossref","is-referenced-by-count":31,"title":["Physician, Practice, and Patient Characteristics Associated With Biosimilar Use in Medicare Recipients"],"prefix":"10.1001","volume":"4","author":[{"given":"Emma Boswell","family":"Dean","sequence":"first","affiliation":[{"name":"Department of Health Management and Policy, Miami Business School, University of Miami, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phyllis","family":"Johnson","sequence":"additional","affiliation":[{"name":"Division of Health Policy and Economics, Department of Population Health Sciences, Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia M.","family":"Bond","sequence":"additional","affiliation":[{"name":"Division of Health Policy and Economics, Department of Population Health Sciences, Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2021,1,27]]},"reference":[{"issue":"10","key":"zoi201053r1","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1377\/hlthaff.2009.0196","article-title":"Biosimilars and the European experience: implications for the United States.","volume":"32","author":"Megerlin","year":"2013","journal-title":"Health Aff (Millwood)"},{"issue":"9","key":"zoi201053r6","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1001\/jamainternmed.2020.3188","article-title":"Uptake of infliximab biosimilars among the Medicare population.","volume":"180","author":"Chen","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"9","key":"zoi201053r8","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1001\/jama.2018.9014","article-title":"Uptake of the biologic filgrastim and its biosimilar product among the Medicare population.","volume":"320","author":"Kozlowski","year":"2018","journal-title":"JAMA"},{"issue":"11","key":"zoi201053r9","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1377\/hlthaff.2019.00253","article-title":"Biosimilar filgrastim uptake and costs among commercially insured, Medicare Advantage.","volume":"38","author":"Karaca-Mandic","year":"2019","journal-title":"Health Aff (Millwood)"},{"issue":"21","key":"zoi201053r10","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1001\/jama.2017.5202","article-title":"Obstacles to the adoption of biosimilars for chronic diseases.","volume":"317","author":"Hakim","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"zoi201053r11","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s11151-018-9630-3","article-title":"The impact of the entry of biosimilars: evidence from Europe.","volume":"53","author":"Scott Morton","year":"2018","journal-title":"Rev Ind Organ"},{"issue":"6","key":"zoi201053r13","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1001\/jamainternmed.2018.7824","article-title":"Favorable formulary placement of branded drugs in Medicare prescription drug plans when generics are available.","volume":"179","author":"Socal","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"4","key":"zoi201053r15","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.jval.2019.12.007","article-title":"Biosimilar uptake in Medicare Part B varied across hospital outpatient departments and physician practices: the case of filgrastim.","volume":"23","author":"Socal","year":"2020","journal-title":"Value Health"},{"key":"zoi201053r16","doi-asserted-by":"crossref","DOI":"10.1007\/s11606-020-05957-1","article-title":"Uptake and usage patterns of biosimilar infliximab in the Medicare population.","author":"Kozlowski","year":"2020","journal-title":"J Gen Intern Med"},{"issue":"8","key":"zoi201053r17","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"147","author":"von Elm","year":"2007","journal-title":"Ann Intern Med"},{"issue":"8","key":"zoi201053r18","doi-asserted-by":"publisher","first-page":"568","DOI":"10.7326\/M19-2838","article-title":"Physician organization and the role of workforce turnover.","volume":"172","author":"Neprash","year":"2020","journal-title":"Ann Intern Med"},{"issue":"1","key":"zoi201053r19","first-page":"102","article-title":"Factors affecting health care provider knowledge and acceptance of biosimilar medicines: a systematic review.","volume":"25","author":"Leonard","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"key":"zoi201053r3"},{"key":"zoi201053r12","volume-title":"Enabling Competition in Pharmaceutical Markets.","author":"Morton","year":"2017"},{"key":"zoi201053r14","volume-title":"Biosimilars: When Lower-Cost Medications Mean Lower Provider Profits","author":"Reddan","year":"2017"},{"key":"zoi201053r2","unstructured":"IQVIA Institute. Medicine use and spending in the U.S. Published 2019. Accessed June 1, 2020. https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports\/medicine-use-and-spending-in-the-us-a-review-of-2018-and-outlook-to-2023"},{"key":"zoi201053r4","unstructured":"Generics and Biosimilars Initiative. Biosimilars approved in Europe. Updated February 21, 2020. Accessed September 17, 2020. http:\/\/www.gabionline.net\/Biosimilars\/General\/Biosimilars-approved-in-Europe"},{"key":"zoi201053r5","unstructured":"US Food and Drug Administration. Biosimilar product information. Updated July 7, 2020. Accessed September 17, 2020. https:\/\/www.fda.gov\/drugs\/biosimilars\/biosimilar-product-information"},{"key":"zoi201053r7","unstructured":"Danosi? C, Haber? A, Simmons-Stern? N, Greenaway? J, Scaife? JG. Why so slow? demystifying the barriers to U.S. biosimilar adoption. Biosimilar Development. Published December 19, 2017. Accessed June 15, 2020. https:\/\/www.biosimilardevelopment.com\/doc\/why-so-slow-demystifying-the-barriers-to-u-s-biosimilar-adoption-0001"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2775641\/dean_2021_oi_201053_1611112265.31329.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T16:31:25Z","timestamp":1611765085000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2775641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,27]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1,4]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.34776","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,27]]}}}